FOXMEYER SALES GROW 16% TO $667 MIL. IN FIRST QUARTER WITH OPERATING EARNINGS AHEAD 40% TO $10 MIL.; PHAR-MOR AGREEMENT WILL HELP FUEL FUTURE GROWTH
Executive Summary
National Intergroup's FoxMeyer wholesale drug subsidiary posted a 16% sales gain to $667 mil. in the first quarter of fiscal 1991. For the three months ended June 30, National Intergroup reported that FoxMeyer generated operating earnings (before goodwill) of $10 mil., up 39% from the same period last year. "The results of the quarter reflect strong independent and institutional sales, along with significant increases in chain store sales from existing and newly added accounts," FoxMeyer President and CEO Robert King said. "At the same time progress continues to be made in reducing costs while maintaining and improving customer service levels." A five-year, $2.8 bil. supply agreement with the drug chain Phar-Mor was announced by National Intergroup management at the company's annual shareholders meeting July 25. The company also said it has picked up additional business from K-mart, which is consolidating its wholesale accounts. FoxMeyer is currently the subject of a tug-of-war between National Intergroup management, which plans to divest all of the diversified companies holdings except FoxMeyer, and a dissident shareholder group, Centaur Partners, which wants to liquidate the entire company, including the wholesale drug business.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth